August 16, 2015 Dear Dr. KSS, Unfortunately, the

New Post Public Reply Private Reply Replies (4) Message Board
sox0407 77luke #21868
August 16, 2015

Dear Dr. KSS,

Unfortunately, the day we spoke was the Thursday the Seeking Alpha article written by an anonymous author was released. With all that was going on, I still honored my appointment for the call with you and others. Perhaps you didn’t know I was at my computer and reading emails from shareholders and others, some shareholders who I have known for years, asking whether the article had any truth to it. Of course there was nothing true to it. Therefore, in retrospect my answers to the group may not have been as clear as I would have hoped them to be due to the events happening real time.

I would like to address some of the points in your article. Perhaps they may (slightly to significantly) change your conclusion.

I agree that Prurisol, from a business perspective, is our riskiest project. The trial only just began and I have no data (yet). The reason we pursued it to the clinic is because the animal data was so compelling. A full response! At this point we are now in the clinical trial and we will all know soon enough.

I actually create wealth for shareholders. I addressed these issues in our press release to shareholders.

I would like to point out that investors during my time at NNVC did very well. I can’t be held responsible as to the actions and to the price of the company after I left.

At CTIX we are working hard to enrich shareholders. I haven’t sold a single share and the company owes me millions of dollars of check deposits I put into the company. That’s the confidence I have in our compounds. Until the other week’s event our shareholders had done very well. I believe we haven’t even scratched the surface of our potential value.

“avowed anticancer agent Kevetrin, as yet with no proven clinical activity, was mired in an ongoing, ceaseless phase 1 trial, with doses being escalated far beyond a clinically appropriate dose in quest for a vaunted “maximum tolerated dose.” [-'Dr' KSS]

Your statement is totally incorrect and is the most important reason why you are drawing the wrong conclusion about Cellceutix.

All patients in all cohorts have their blood drawn and sent for “PK” analysis. The clinical investigator’s and our teams see the results and the Safety Review Committee decides whether to increase dosing is made based on this and safety data. If the “PK” data indicates the higher dose is more effective, of course we will increase dosing. Our recent statements that we expect to conclude the trial soon means the rate of increased benefit to increased dosing is getting narrower. It has zero to do with lets give the patient more drug.

About the clinical benefits of Kevetrin, we have released ASCO posters and certain other information through press releases that should reassure one of the enormous potential of the drug. Our last press release mentioned a patient in our trial now in his 11th month on Kevetrin and had stable disease. The important read is the time, 11 months. I want to direct you to

http://seekingalpha.com/news/2593255-epizymes...33-percent

Epizyme's tazemetostat demonstrates 60% response rate in advanced lymphoma; shares jump 33%

Some points to note:

Epizyme stock went way over a billion dollar market cap.

The article states:

"The patient with the EZH2 mutation, who was refractory or had relapsed to six previous treatment regimens, achieved a partial response after 16 weeks of therapy and remains on study."

"One patient remains on study at 18 months of treatment. Three of five (60%) evaluable patients with follicular lymphoma achieved an objective response. One patient with a complete response remains on study at 13 months as is one patient with a partial response."

Well all our patients are refractory tumors. Our trial is a much more difficult trial. We are dealing with all very late stage solid tumors (and different) which in most patients has metastasized to other organs. In a blood cancer you are injecting the drug directly into the tumors, unlike our trial. Once we select cancers for Phase 2 studies, dosing methods and strategies likely change.

I wish our patient mentioned above many many more years of life and I hope Kevetrin helps him to achieve this.

A few other important points:

We do not hire promoters!

Regarding “ENROLLING BY INVITATION ONLY,” we used the same clinical sites that all the other approved ABSSSI drugs used. Why they request this language, I do not know. Perhaps it’s because patients are from the Hospitals emergency room and are not recruited elsewhere. I can look into this.

You are completely misinformed about the physicians we recruited for our board of directors. It is the exact opposite of what you state. I wanted physicians with lots and lots of clinical trial experience who also have practices. These physicians understand the drug reimbursement policies of insurance companies. They both run clinical trials for big pharma. Many trials. They are key opinion leaders and consult for Novartis and others. They bring enormous value to our shareholders.

Last week the reporter from Boston Business and some shareholders visited our offices and the labs directly behind our offices. Our premises were formerly occupied by Cell Signaling. Very high quality labs that we even upgraded. I assure you that the labs, significantly larger than the office space is used and significant research is going on there.

Well, please visit us in Beverly and see for yourself.

At CTIX we don't sleep on our accomplishments to date. We are always planning for additional trials and growth of CTIX. I notice that you are a gastroenterologist. I want to share with you some of Drs Alexander and Menon’s notes sent to me from this years meeting in Orlando with key GI opinion leaders. (Attached) I would like to present you with a question. If you were in my shoes what would you do? There is grant money which is being used to study our gram negative compounds. We can try to speed up development by spending an enormous sum of money and then need to do a tox, phase 1, and efficacy in humans will only be known in Phase 2. Or wait until definitive data comes in from the oral mucositis trial and then we are close to certainty the drug will be effective for ulcerative proctitis, ulcerative colitis, crohns and IBD. Of course for crohns and IBD we will need to develop an oral formulation. I will go by your expertise but I have been told by other GI physicians the market for these diseases will certainly generate much greater revenues to CTIX with much less risk.

I hope you will be open minded and take the time to reassess your opinion of Cellceutix with what I have shared with you. You are welcome to visit us in our labs and there you will learn a lot more about Cellceutix which will amaze you!

Leo Ehrlich

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
Dont-give-up.jpg
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Clear Aligner Results Depend on Discipline, Not Hype

Updated Category News Views 115

A Clear Tray Is Not a Magic Wand Transparent orthodontic trays sell a wonderfully tidy idea: straighten teeth without the metal-and-wire routine, take them out to eat, and carry on. Fair enough. But the useful message from Dr. Theresa Trapp is the part nobody should glide past: clear aligners are a treatment plan, not a cosmetic shortcut bought with good intentions....

Continue Reading
Alabama Power's 2027 Cut Puts Data Centers to Work

Updated Category News Views 107

Data centers rarely arrive bearing a gift for ordinary power customers. Yet Alabama Power says its coming load growth will help cut customer rates by $160 million in 2027, beginning with January bills. In a utility world stuffed with requests for more money, that is a sharp change of pace. The company filed the reduction with the Alabama Public Service Commission on Nov....

Continue Reading
ECW Puts $52 Million Behind Learning Through Crisis

Updated Category News Views 66

A reserve fund for a classroom is not glamorous, but it may be the smartest detail in this whole $52 million commitment. Education Cannot Wait has announced support for more than 300,000 children in Lebanon, Myanmar and South Sudan, where war, flooding and displacement have ripped ordinary schooling apart. The money is meant to restore learning, provide catch-up classes...

Continue Reading
North Richland Hills Bets on Its Visitor Momentum Now

Updated Category News Views 65

A crowded family attraction map is a nice problem for a Texas city to have, and North Richland Hills is trying to turn that pile of assets into a cleaner regional tourism machine. On Nov. 20, 2026, the city introduced “The Place You Never Outgrow,” its first destination-marketing campaign, built with Flat Five Marketing. This is not a stock story in the usual...

Continue Reading
Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 120

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading
Africa Tech Festival Puts Trust Ahead of AI Hype Cycle

Updated Category News Views 75

Fifteen thousand people can fill a convention centre, but they cannot magically deliver a package, fund a small business, or repair harm from a bad automated decision. That rather useful dose of reality ran through the final day of Africa Tech Festival 2026 in Cape Town. The 29th edition drew more than 15,000 delegates across three days, and the strongest message was not...

Continue Reading
Flair's New Aviation Alliance Offers Options, Not Orders

Updated Category News Views 70

Aircraft shortages have a funny way of turning vague partnerships into very useful insurance policies. Flair Airlines, Phoenix Aviation Capital and Avia Solutions Group announced a Strategic Commercial Cooperation Agreement on Nov. 19, 2026, and the sensible reading is straightforward: the Canadian value carrier wants more ways to solve capacity and operational problems...

Continue Reading
QuidelOrtho Faces Fresh Scrutiny Over Savanna Claims

Updated Category News Views 72

A diagnostic launch can turn into a corporate migraine with frightening speed, and QuidelOrtho is staring at exactly that sort of mess. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether QuidelOrtho officers or directors breached fiduciary duties or otherwise violated state or federal law. This is not a finding of wrongdoing. It is an...

Continue Reading
Epiroc Takes Live Remote Drilling to CES 2027 Stage

Updated Category News Views 48

A drill rig chewing through Virginia rock from a Las Vegas convention booth is either a serious industrial-tech moment or an expensive magic trick. At CES 2027, Epiroc intends to make the distinction painfully clear. From January 6 through 9, the Stockholm-based mining-equipment company and Luck Stone will connect Booth 7031 in the LVCC West Hall to a working quarry in...

Continue Reading
CVRx Lawsuit Puts Barostim Sales Claims Under Hard Scrutiny

Updated Category News Views 121

August 7 turned a compliance disclosure into a wrecking ball for CVRx shareholders. After the company revealed a Department of Justice civil investigative demand and cut its outlook, the stock dropped $3.55, or 60%, to close at $2.39. That is not a routine bad quarter getting punished. It is the market abruptly questioning whether the sales engine, the revenue it...

Continue Reading

Top 5 Most Recently Viewed Articles

Beyond Finance Secures Legal Win with Permanent Injunction

Updated Category News Views 1608

Legal Victory for Beyond Finance Against Former Executive In a significant legal development, Beyond Finance has successfully secured a permanent injunction against its former Chief Marketing Officer, Grant Eckert. This ruling was handed down by a Texas court, illustrating a firm stance by Beyond Finance in upholding its non-competition agreements. Details of the Case The...

Continue Reading
Analyzing the Decline in Serve Robotics Inc's Short Interest

Updated Category News Views 174

Understanding Serve Robotics Inc's Short Interest Trends Serve Robotics Inc (NYSE: SERV) has recently reported a noticeable decline in its short interest, down by 6.79% from the previous report. As of the latest data, around 13.64 million shares have been sold short, representing 19.08% of all available shares for trading. Notably, it would take traders an average of 1.53...

Continue Reading
FAT Brands Stock Trend Analysis: 52-Week Low Challenges

Updated Category News Views 147

FAT Brands Faces Market Challenges at 52-Week Low In recent trading activities, FAT Brands Inc., trading under the ticker FATBB, has encountered significant market challenges, recently dropping to a 52-week low of $4.13. This recent low is indicative of the difficulties the company is facing amidst a shifting economic environment. Market Dynamics Affecting FAT Brands...

Continue Reading
Kraig Labs Leads the Charge in Revolutionary Silk Fabrication

Updated Category News Views 221

Kraig Labs: Pioneering Spider Silk Innovation In recent years, the realm of biotechnology has witnessed significant advancements, particularly in the production of specialized materials. Kraig Biocraft Laboratories, or Kraig Labs, stands at the forefront of this innovative field, redefining the future of spider silk. This biotechnology company has gained recognition for...

Continue Reading
The Safar Twins Unveil Stunning Short Film Resonance

Updated Category News Views 395

The Safar Twins Unveil a Captivating New Short Film Written and directed by interdisciplinary artist Parsa Afsharjavan, Resonance is an upcoming cinematic gem that promises to captivate audiences worldwide. This 30-minute short film, inspired by the intricate themes of duality and identity, is set to premiere in 2025 and navigate the global festival circuit. Introducing...

Continue Reading